SRC
ABBV icon

Sage Rhino Capital’s AbbVie ABBV Stock Holding History

Sage Rhino Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$570K Sell
2,265
-52
-2% -$11.2K 0.09% 143
2026
Q1 		$504K Sell
2,317
-6
-0.3% -$1.33K 0.09% 145
2025
Q4 		$531K Sell
2,323
-107
-4% -$24.4K 0.1% 142
2025
Q3 		$563K Buy
2,430
+125
+5% +$25.5K 0.11% 139
2025
Q2 		$428K Buy
2,305
+5
+0.2% +$929 0.09% 143
2025
Q1 		$482K Sell
2,300
-17
-0.7% -$3.31K 0.11% 137
2024
Q4 		$412K Sell
2,317
-63
-3% -$11.6K 0.09% 148
2024
Q3 		$470K Sell
2,380
-71
-3% -$13.3K 0.1% 143
2024
Q2 		$420K Buy
2,451
+102
+4% +$16.9K 0.1% 140
2024
Q1 		$428K Buy
2,349
+85
+4% +$14.6K 0.1% 142
2023
Q4 		$351K Sell
2,264
-41
-2% -$5.98K 0.09% 144
2023
Q3 		$344K Buy
2,305
+28
+1% +$4.11K 0.1% 146
2023
Q2 		$307K Sell
2,277
-406
-15% -$59.5K 0.09% 157
2023
Q1 		$428K Buy
2,683
+368
+16% +$56.3K 0.12% 128
2022
Q4 		$374K Sell
2,315
-2
-0.1% -$307 0.12% 134
2022
Q3 		$311K Sell
2,317
-171
-7% -$24.5K 0.12% 124
2022
Q2 		$381K Sell
2,488
-308
-11% -$47.1K 0.15% 117
2022
Q1 		$453K Sell
2,796
-35
-1% -$5.08K 0.14% 127
2021
Q4 		$383K Buy
2,831
+75
+3% +$8.86K 0.11% 138
2021
Q3 		$297K Buy
2,756
+71
+3% +$8.11K 0.09% 151
2021
Q2 		$302K Buy
2,685
+59
+2% +$6.64K 0.09% 152
2021
Q1 		$284K Buy
2,626
+40
+2% +$4.28K 0.09% 139
2020
Q4 		$277K Buy
2,586
+29
+1% +$2.79K 0.11% 137
2020
Q3 		$224K Sell
2,557
-5
-0.2% -$471 0.11% 137
2020
Q2 		$252K Buy
+2,562
New +$226K 0.13% 124

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sage Rhino Capital's ABBV Position: Q2 2026 in Review

Sage Rhino Capital reduced its AbbVie (ABBV) stake by 2.2% in Q2 2026, selling an estimated $11.2K and leaving 2,265 shares worth $570K. The position accounts for 0.09% of the portfolio, ranked #143.

Sage Rhino Capital first reported a position in ABBV in Q2 2020 and has held it in 25 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Sage Rhino Capital held 2,265 shares of AbbVie worth $570K as of Q2 2026.
  • Sage Rhino Capital sold 52 AbbVie shares in Q2 2026, an estimated $11.2K.
  • AbbVie made up 0.09% of Sage Rhino Capital's portfolio in Q2 2026, its #143 holding.
  • Sage Rhino Capital first reported a position in AbbVie in Q2 2020 and has held it in 25 quarters since.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sage Rhino Capital's 13F filing for Q2 2026, filed 3 Aug 2026.